Skip to main content
Erschienen in: Esophagus 2/2021

09.09.2020 | Original Article

Immunohistochemical expression of filaggrin is decreased in proton pump inhibitor non-responders compared with proton pump inhibitor responders of eosinophilic esophagitis

verfasst von: Nahoko Nagano, Asuka Araki, Noriyoshi Ishikawa, Mamiko Nagase, Kyoichi Adachi, Norihisa Ishimura, Shunji Ishihara, Yoshikazu Kinoshita, Riruke Maruyama

Erschienen in: Esophagus | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Eosinophilic esophagitis (EoE) is an allergic gastrointestinal disease that features eosinophilic infiltration of esophageal mucosa, but the role of barrier dysfunction of the epithelium in its pathogenesis remains to be elucidated. Clinically, EoE is divided into proton pump inhibitor-non-responders (PPI-NR) and PPI-responders (PPI-R). Our main aims were to investigate the differences of expression of epidermal differential complex (EDC) proteins and desmoglein that are considered to play important roles in formation of the epidermal skin barrier between these two conditions and to seek the usefulness of the differences in pathological diagnosis. Conventional histopathological findings and allergic background were also compared.

Methods

Twenty-nine PPI-NR and 44 PPI-R were recruited, and 35 reflux esophagitis patients were also enrolled. After clinical information and histopathological findings were reviewed, immunohistochemical expression of EDC proteins (filaggrin, loricrin, and involucrin) and desmoglein in all three groups were examined and semi-quantitatively scored.

Results

Regarding allergic conditions, the prevalence of asthma was significantly higher in PPI-NR than in PPI-R. Other allergic conditions showed no differences. Histopathological findings did not exhibit the statistical difference between PPI-NR and PPI-R. However, immunostaining score of filaggrin in PPI-NR was significantly lower than in PPI-R, although the expressions of involucrin, loricrin and desmoglein demonstrated no differences.

Conclusions

The results suggest a role of reduced filaggrin expression in the difference of effectiveness of PPI treatment between PPI-NR and PPI-R. Moreover, immunohistochemical determination of filaggrin expression in EoE patients could be informative in the clinical decision of how to treat the patients.
Literatur
1.
Zurück zum Zitat Kinoshita Y, Ishimura N, Oshima N, et al. Recent progress in the research of eosinophilic esophagitis and gastroenteritis. Digestion. 2016;93:7–12.CrossRef Kinoshita Y, Ishimura N, Oshima N, et al. Recent progress in the research of eosinophilic esophagitis and gastroenteritis. Digestion. 2016;93:7–12.CrossRef
2.
Zurück zum Zitat Kinoshita Y, Oouchi S, Fujisawa T. Eosinophilic gastrointestinal diseases—pathogenesis, diagnosis, and treatment. Allergol Int. 2019;68:420–9.CrossRef Kinoshita Y, Oouchi S, Fujisawa T. Eosinophilic gastrointestinal diseases—pathogenesis, diagnosis, and treatment. Allergol Int. 2019;68:420–9.CrossRef
3.
Zurück zum Zitat Cabanillas B, Novak N. Atopic dermatitis and filaggrin. Curr Opin Immunol. 2016;42:1–8.CrossRef Cabanillas B, Novak N. Atopic dermatitis and filaggrin. Curr Opin Immunol. 2016;42:1–8.CrossRef
4.
Zurück zum Zitat Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134:792–9.CrossRef Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134:792–9.CrossRef
5.
Zurück zum Zitat Blanchard C, Stucke EM, Burwinkel K, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol. 2010;184:4033–41.CrossRef Blanchard C, Stucke EM, Burwinkel K, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol. 2010;184:4033–41.CrossRef
6.
Zurück zum Zitat Sherrill JD, Kc K, Wu D, et al. Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. Mucosal Immunol. 2014;7:718–29.CrossRef Sherrill JD, Kc K, Wu D, et al. Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. Mucosal Immunol. 2014;7:718–29.CrossRef
7.
Zurück zum Zitat Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:13–22.CrossRef Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:13–22.CrossRef
8.
Zurück zum Zitat Molina-Infante J, Katzka DA, Gisbert JP. Review article: Proton pump inhibitor therapy for suspected eosinophilic oesophagitis. Aliment Pharmacol Ther. 2013;37:1157–64.CrossRef Molina-Infante J, Katzka DA, Gisbert JP. Review article: Proton pump inhibitor therapy for suspected eosinophilic oesophagitis. Aliment Pharmacol Ther. 2013;37:1157–64.CrossRef
9.
Zurück zum Zitat Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3–20.CrossRef Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3–20.CrossRef
10.
Zurück zum Zitat Molina-Infante J, Rivas MD, Hernandez-Alonso M, et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. Aliment Pharmacol Ther. 2014;40:955–65.CrossRef Molina-Infante J, Rivas MD, Hernandez-Alonso M, et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. Aliment Pharmacol Ther. 2014;40:955–65.CrossRef
11.
Zurück zum Zitat van Rhijn BD, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014;12:1815–23.CrossRef van Rhijn BD, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014;12:1815–23.CrossRef
12.
Zurück zum Zitat Jiao D, Ishimura N, Maruyama R, et al. Similarities and differences among eosinophilic esophagitis, proton-pump inhibitor-responsive esophageal eosinophilia, and reflux esophagitis: comparisons of clinical, endoscopic, and histopathological findings in Japanese patients. J Gastroenterol. 2017;52:203–10.CrossRef Jiao D, Ishimura N, Maruyama R, et al. Similarities and differences among eosinophilic esophagitis, proton-pump inhibitor-responsive esophageal eosinophilia, and reflux esophagitis: comparisons of clinical, endoscopic, and histopathological findings in Japanese patients. J Gastroenterol. 2017;52:203–10.CrossRef
13.
Zurück zum Zitat Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J. 2017;5:335–58.CrossRef Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J. 2017;5:335–58.CrossRef
14.
Zurück zum Zitat Oshima N, Ishihara S, Fukuba N, et al. Epidermal differentiation complex protein involucrin is down-regulated in eosinophilic esophagitis. Esophagus. 2017;14:171–7.CrossRef Oshima N, Ishihara S, Fukuba N, et al. Epidermal differentiation complex protein involucrin is down-regulated in eosinophilic esophagitis. Esophagus. 2017;14:171–7.CrossRef
15.
Zurück zum Zitat Matoso A, Mukkada VA, Lu S, et al. Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis. Mod Pathol. 2013;26:665–76.CrossRef Matoso A, Mukkada VA, Lu S, et al. Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis. Mod Pathol. 2013;26:665–76.CrossRef
16.
Zurück zum Zitat Wu L, Oshima T, Li M, et al. Filaggrin and tight junction proteins are crucial for IL-13-mediated esophageal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol. 2018;315:G341–50.CrossRef Wu L, Oshima T, Li M, et al. Filaggrin and tight junction proteins are crucial for IL-13-mediated esophageal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol. 2018;315:G341–50.CrossRef
17.
Zurück zum Zitat Politi E, Angelakopoulou A, Grapsa D, et al. Filaggrin and periostin expression is altered in eosinophilic esophagitis and normalized with treatment. J Pediatr Gastroenterol Nutr. 2017;65:47–52.CrossRef Politi E, Angelakopoulou A, Grapsa D, et al. Filaggrin and periostin expression is altered in eosinophilic esophagitis and normalized with treatment. J Pediatr Gastroenterol Nutr. 2017;65:47–52.CrossRef
18.
Zurück zum Zitat Marietta EV, Geno DM, Smyrk TC, et al. Presence of intraepithelial food antigen in patients with active eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;45:427–33.CrossRef Marietta EV, Geno DM, Smyrk TC, et al. Presence of intraepithelial food antigen in patients with active eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;45:427–33.CrossRef
19.
Zurück zum Zitat Davis BP. Pathophysiology of eosinophilic esophagitis. Clin Rev Allergy Immunol. 2018;55:19–42.CrossRef Davis BP. Pathophysiology of eosinophilic esophagitis. Clin Rev Allergy Immunol. 2018;55:19–42.CrossRef
20.
Zurück zum Zitat Muir AB, Wang JX, Nakagawa H. Epithelial-stromal crosstalk and fibrosis in eosinophilic esophagitis. J Gastroenterol. 2019;54:10–8.CrossRef Muir AB, Wang JX, Nakagawa H. Epithelial-stromal crosstalk and fibrosis in eosinophilic esophagitis. J Gastroenterol. 2019;54:10–8.CrossRef
22.
Zurück zum Zitat Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2013;62:824–32.CrossRef Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2013;62:824–32.CrossRef
23.
Zurück zum Zitat Zhang X, Cheng E, Huo X, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One. 2012;7:e50037.CrossRef Zhang X, Cheng E, Huo X, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One. 2012;7:e50037.CrossRef
24.
Zurück zum Zitat Tanaka F, Fukumoto S, Morisaki T, et al. Obesity and hiatal hernia may be non-allergic risk factors for esophageal eosinophilia in Japanese adults. Esophagus. 2019;16:309–15.CrossRef Tanaka F, Fukumoto S, Morisaki T, et al. Obesity and hiatal hernia may be non-allergic risk factors for esophageal eosinophilia in Japanese adults. Esophagus. 2019;16:309–15.CrossRef
25.
Zurück zum Zitat Durrani SR, Mukkada VA, Guilbert TW. Eosinophilic esophagitis: an important comorbid condition of asthma? Clin Rev Allergy Immunol. 2018;55:56–64.CrossRef Durrani SR, Mukkada VA, Guilbert TW. Eosinophilic esophagitis: an important comorbid condition of asthma? Clin Rev Allergy Immunol. 2018;55:56–64.CrossRef
26.
Zurück zum Zitat González-Cervera J, Arias Á, Redondo-González O, et al. Association between atopic manifestations and eosinophilic esophagitis: a systematic review and meta-analysis. Ann Allergy Asthma Immunol Am Coll Allergy Asthma Immunol. 2017;118:582–90 (e2).CrossRef González-Cervera J, Arias Á, Redondo-González O, et al. Association between atopic manifestations and eosinophilic esophagitis: a systematic review and meta-analysis. Ann Allergy Asthma Immunol Am Coll Allergy Asthma Immunol. 2017;118:582–90 (e2).CrossRef
28.
Zurück zum Zitat Padia R, Curtin K, Peterson K, et al. Eosinophilic esophagitis strongly linked to chronic rhinosinusitis. Laryngoscope. 2016;126:1279–83.CrossRef Padia R, Curtin K, Peterson K, et al. Eosinophilic esophagitis strongly linked to chronic rhinosinusitis. Laryngoscope. 2016;126:1279–83.CrossRef
29.
Zurück zum Zitat Iwakura N, Fujiwara Y, Tanaka F, et al. Basophil infiltration in eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther. 2015;41:776–84.CrossRef Iwakura N, Fujiwara Y, Tanaka F, et al. Basophil infiltration in eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther. 2015;41:776–84.CrossRef
30.
Zurück zum Zitat Ishimura N, Kinoshita Y. Eosinophilic esophagitis in Japan: Focus on response to acid suppressive therapy. J Gastroenterol Hepatol. 2018;33:1016–22.CrossRef Ishimura N, Kinoshita Y. Eosinophilic esophagitis in Japan: Focus on response to acid suppressive therapy. J Gastroenterol Hepatol. 2018;33:1016–22.CrossRef
Metadaten
Titel
Immunohistochemical expression of filaggrin is decreased in proton pump inhibitor non-responders compared with proton pump inhibitor responders of eosinophilic esophagitis
verfasst von
Nahoko Nagano
Asuka Araki
Noriyoshi Ishikawa
Mamiko Nagase
Kyoichi Adachi
Norihisa Ishimura
Shunji Ishihara
Yoshikazu Kinoshita
Riruke Maruyama
Publikationsdatum
09.09.2020
Verlag
Springer Singapore
Erschienen in
Esophagus / Ausgabe 2/2021
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-020-00781-2

Weitere Artikel der Ausgabe 2/2021

Esophagus 2/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.